New York-based Sycamore Partners is acquiring Walgreens for $11.45 a share in cash, the companies announced Thursday.
Moderna says its long-running patent dispute with Pfizer and BioNTech isn't over even after a decision by an administrative ...
With big tech players touting new ways they’re offering AI in healthcare, it’s feeling more and more like AI’s built in, not ...
CordenPharma expands in Europe/US, FDA warns Granules India, Cytiva cuts jobs, Mustang Bio sells to AbbVie, EFPIA sues EU, ...
Frazier Life Sciences, a decades-old biotech investor, is raising another heap of dry powder to create and invest in startups ...
Novo Nordisk's rare disease unit awaits Phase 3 data for etavopivat in sickle cell disease, aiming for 50% VOC reduction ...
Luxa Biotechnology said Thursday that its stem cell therapy helped improve vision in a handful of people with a common form ...
Merck KGaA's lupus drug enpatoran fails Phase 2 trial, Zymeworks halts ZW220 development, Tris Pharma's cebranopadol succeeds in pain trial, ARS Pharma's neffy gets pediatric approval ...
Merck KGaA CEO Belén Garijo says Trump's China tariffs impact manageable due to regionalized supply chains; company reports 2 ...
Denali Therapeutics’ ALS program showed no effect on an important neurodegeneration biomarker that could have been used for ...
Trump’s FDA pick Martin Makary goes before the Senate today, giving one of the first glimpses at what his priorities ...
Novo Nordisk got the green light to join a lawsuit by compounders against the FDA after the agency deemed that the Danish ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback